DOVA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DOVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Dova Pharmaceuticals's change in inventory for the quarter that ended in Sep. 2019 was $-0.52 Mil. It means Dova Pharmaceuticals's inventory increased by $0.52 Mil from Jun. 2019 to Sep. 2019 .
Dova Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2018 was $-4.39 Mil. It means Dova Pharmaceuticals's inventory increased by $4.39 Mil from Dec. 2017 to Dec. 2018 .
Dova Pharmaceuticals's Total Inventories for the quarter that ended in Sep. 2019 was $4.68 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Dova Pharmaceuticals's Days Inventory for the quarter that ended in Sep. 2019 was 618.35.
Inventory Turnover measures how fast the company turns over its inventory within a year. Dova Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2019 was 0.15.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Dova Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2019 was 1.31.
The historical data trend for Dova Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dova Pharmaceuticals Annual Data | |||||||
Trend | Dec16 | Dec17 | Dec18 | ||||
Change In Inventory | - | - | -4.39 |
Dova Pharmaceuticals Quarterly Data | ||||||||||||||
Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | |
Change In Inventory | Get a 7-Day Free Trial | -1.22 | -2.61 | 0.08 | 0.14 | -0.52 |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dova Pharmaceuticals (NAS:DOVA) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Dova Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 4.425 | / | 0.653 | * | 365 / 4 | |
= | 618.35 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Dova Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2019 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0.653 | / | 4.425 | |
= | 0.15 |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Dova Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2019 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 4.425 | / | 3.373 | |
= | 1.31 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Dova Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Nancy Wysenski | director | 2200 SUNBURST STREET, CHATSWORTH CA 90401 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Allen Lee F Md Phd | officer: Chief Medical Officer | C/O AMAG PHARMACEUTICALS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE MA 02140 |
Roger Jeffs | director | |
Alfred J Novak | director | 325 NE 6TH ST, BOCA RATON FL 33432 |
David Zaccardelli | director, officer: President & CEO | 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069 |
Paul B Manning | director, 10 percent owner | 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902 |
Stalfort John A Iii | director | C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902 |
Jason Hoitt | officer: Chief Commercial Officer | C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707 |
Alex Sapir | director, officer: President & CEO | C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707 |
From GuruFocus
By Marketwired Marketwired • 10-29-2019
By Marketwired Marketwired • 03-06-2019
By Marketwired Marketwired • 10-13-2019
By Marketwired Marketwired • 06-27-2019
By Marketwired Marketwired • 06-25-2019
By Marketwired Marketwired • 06-24-2019
By Marketwired Marketwired • 12-21-2018
By Marketwired Marketwired • 09-26-2019
By Marketwired Marketwired • 05-20-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.